SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 17, 2021 08:30 ET
|
Scynexis
Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon...
SCYNEXIS Secures Term Loan Facility for up to $60 Million with Hercules Capital and Silicon Valley Bank
May 14, 2021 08:30 ET
|
Scynexis
Together with SCYNEXIS’ $93M cash balance at 12/31/20, the non-dilutive capital injections from this term loan, the recent licensing payments from Hansoh Pharma, and the monetization of 2020 New...
SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch
May 11, 2021 08:30 ET
|
Scynexis
Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and...
SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections
April 30, 2021 08:00 ET
|
Scynexis
A single-day dose of oral ibrexafungerp demonstrates positive clinical outcomes in difficult-to-treat vulvovaginal candidiasis (VVC) patient populations: those with non-albicans Candida VVC and/or...
SCYNEXIS to Present Two Ibrexafungerp (Brexafemmeᵀᴹ) Posters at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting
April 20, 2021 08:00 ET
|
Scynexis
JERSEY CITY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 29, 2021 08:20 ET
|
Scynexis
FDA accepted SCYNEXIS’ New Drug Application (NDA) for oral ibrexafungerp for the treatment of vaginal yeast infections, conditionally approved the brand name BrexafemmeTM, and granted priority review...
SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
March 02, 2021 07:30 ET
|
Scynexis
Consistent with prior two interim analyses, FURI results confirm positive clinical activity of oral ibrexafungerp in patients with difficult-to-treat, severe, mucocutaneous and invasive fungal...
SCYNEXIS to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event
February 25, 2021 16:15 ET
|
Scynexis
JERSEY CITY, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS and Amplity Health Announce Agreement to Support the Anticipated U.S. Commercialization of BrexafemmeTM (Ibrexafungerp) for Vaginal Yeast Infections
February 23, 2021 08:15 ET
|
Scynexis
Synergistic combination of Amplity’s proven commercial sales capabilities and SCYNEXIS’ internal medical, marketing, and strategic expertise will maximize Brexafemme’s commercial potential while...
SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China
February 17, 2021 08:15 ET
|
Scynexis
Hansoh Pharma, one of the largest biopharmaceutical companies in Greater China and in Asia, provides fully integrated R&D, manufacturing, and commercial capabilities to accelerate entry of...